" If the company releases stunning data, then most of these options won't be funded by selling the heads on market because that makes no sense."
That's exactly my point, hardly anything makes sense at the ASX these days. ALA's EV about $185m and still no clinical trial. CHM got runs on the board, EV about $5m. No listed comp in AUS got more clinical cell therapy trials than CHM plus so far 3 out of 4 have delivered and yet......
ALA's Baker talking up ALA, securing $20m of funding at hardly any discount. Hopper on the other hand used a great result to half the sp for less than $5m, and that twice. Once after the GBM read out and last year after the NK update.
So again, what does make sense?
CHM Price at posting:
0.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)